Abstract

The introduction of reduced-intensity conditioning regimens has allowed elderly patients with preexisting comorbidities access to the potentially curative allogeneic stem cell transplantation. Patient's comorbidities at the time of treatment consideration play a significant role in transplant outcome in terms of both overall survival (OS) and nonrelapse mortality (NRM). The hematopoietic stem cell transplantation comorbidity index (HCT-CI) quantifies these patient specific risks and has established itself as a major tool in the pretransplant assessment of patients. Many single center and multicenter studies have assessed the HCT-CI score and reported conflicting outcomes. The present study aimed to evaluate the HCT-CI in a single large European transplant centre. 245 patients were retrospectively analyzed and the predictive value of the score was assessed with respect to OS and NRM. We confirm that the HCT-CI predicts outcome for both OS and NRM. Moreover, we identified age of the patient as an independent prognostic parameter for OS. Incorporation of age in the HCT-CI would improve its ability to prognosticate and allow the transplant physician to assess the patient specific risks appropriately at the time of counseling for transplant.

Highlights

  • Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapeutic option for a variety of haematological malignancies [1]

  • The present study aimed to evaluate the hematopoietic stem cell transplantation comorbidity index (HCT-CI) in a single large European transplant centre. 245 patients were retrospectively analyzed and the predictive value of the score was assessed with respect to overall survival (OS) and nonrelapse mortality (NRM)

  • Increase in the average age of the cancer patients has led to a concerted effort in developing scoring systems which help in predicting outcomes following treatment [17]

Read more

Summary

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapeutic option for a variety of haematological malignancies [1]. Lack of inclusion of significant comorbidities like preexisting infections and stringent pretransplant exclusion criteria meant that in the HSCT setting CCI had very low sensitivity to identify the patients at a higher risk of a TRM. This leads to the development of hematopoietic cell transplantationcomorbidity index (HCT-CI) [7]. Retrospective reviews performed in various institutions gave conflicting reports [8,9,10,11,12,13,14] This retrospective study aims to assess the ability of HCT-CI to predict outcome with respect to OS and NRM in a large German single center transplant unit, University of Cologne, Germany

Patients and Methods
Results
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call